Value and progress of biomarkers in predicting the response of anti-tumor necrosis factor-α monoclonal antibody in the treatment of inflammatory bowel disease
10.3760/cma.j.cn101480-20201017-00114
- VernacularTitle:生物标记物对预测抗肿瘤坏死因子-α单克隆抗体治疗炎症性肠病反应的价值及进展
- Author:
Yunping CAI
1
;
Qianhong TAO
;
Jiahui WANG
;
Wen LYU
Author Information
1. 南京医科大学附属杭州医院消化内科，杭州 310006
- Publication Type:Journal Article
- Keywords:
Inflammatory bowel disease;
Biomarker;
Anti-tumor necrosis factor;
Primary non-response;
Secondary non-response;
Prediction
- From:
Chinese Journal of Inflammatory Bowel Diseases
2021;05(4):347-351
- CountryChina
- Language:Chinese
-
Abstract:
Biologics have become the first-line drugs in the treatment of moderate to severe inflammatory bowel disease (IBD) , and anti-tumor necrosis factor-α (TNF-α) monoclonal antibodies are widely used now. However, during the course of treatment, patients′ primary non-response and secondary failure often occur. This article mainly reviews some related biomarkers from the perspectives of genetics, cytokines, intestinal microbiome and routine laboratory indicators to predict the response of anti-TNF-α monoclonal antibodies, and then monitor the efficacy of drugs to help the clinicians to switch the treatment and optimize the therapeutic schedule in time.
